

Pharmacy Formulary Updates for May 2020

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status May 2020:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Together ACO - MA
Flonase Sensimist	\$3.65;PA
Vyondys 53	MB;PA
Oxbryta	\$3.65;PA;SP available
Adakveo	MB;PA
Ayvakit	\$3.65;PA;QL(1/day)
Tazverik	\$3.65;PA
Ruxience	MB;PA
Asceniv	MB/RX;PA;SP avail
Caplyta (lumateperon tosylate)	MB;PA
HIZENTRA INJ 2GM/10ML	MB/RX;PA;SP avail
HIZENTRA INJ 1GM/5ML	MB/RX;PA;SP avail
HIZENTRA SOL 20%	MB/RX;PA;SP avail
Zinplava	MB
Tysabri	MB
Aliqopa	MB
Kynamro	\$3.65;QL (4 units/28 days)

Key

- MB:** Medical Benefit
- NC:** Not covered
- NTM:** New-to-market
- PA:** Prior Authorization
- MB/RX:** Drug can be dispensed through Medical Benefit or Prescription Benefit
- QL:** Quantity Limitation
- SP:** Specialty Pharmacy - provided through CVS/specialty
- ST:** Step Therapy